Kintara Therapeutics Inc

NASDAQ:KTRAUnited States

Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to available therapies, with particular focus on orphan cancer indications. The Company’s two lead candidates include VAL-083 and REM-001. Its VAL-083 is a novel, validated, deoxyribonucleic acid (DNA) targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG) The Company’s REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC); basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients.

Contact Information

Headquarters

9920 Pacific Heights Blvd Suite 150, Suite 200SAN DIEGO, CA, United States 92121

Phone

858-350-4364

Fax

604-202-1384

Executives

Chairman of the Board, President, Chief Executive Officer

Robert Hoffman

Chief Financial Officer

Scott Praill

Senior Vice President, Business Development

John Liatos

Chief Scientific Officer

Dennis Brown

Vice President - Research & Development

Steven Rychnovsky